Aquafeed Journal publishes article on Menon pathogen detection system at point-of-need for aquaculture
Aquafeed Journal has published an article on Menon’s point-of-need system and assays for microbial monitoring of aquaculture hatcheries, pathogen detection in shrimp and fish farms and seafood processing facilities in its recent issue published in April 2015.
SAN DIEGO, April 30, 2015 – Menon Biosensors, Inc. (MBI) has developed and validated a Lab-in-the-Box pathogen detector using its M2 (Molecular Mirroring) nuclear magnetic resonance (NMR) and nanoparticle technology. Aquafeed Journal has recently published an article highlighting Menon’s point-of-need system and proprietary assays for microbial monitoring in aquaculture hatcheries, pathogen detection in aquaculture farms and seafood screening in processing facilities. Several challenges facing the aquaculture industry today can be solved using Menon’s system and assays. The M2 technology can rapidly and accurately detect pathogens in aquaculture ponds and hatcheries by processing water, soil, animal tissue, animal feces, and feed.
In the Aquafeed article, the Menon system and assays have been described as a powerful tool to rapidly detect the pathogen that causes a deadly shrimp disease known as “Early Mortality Syndrome” (EMS) or “Acute Hepatopancreatic Necrosis Disease” (AHPND). The disease is presently found in many shrimp farming countries and is spreading worldwide causing substantial economic losses. The causative agent of EMS/AHPND has been identified as a pathogenic Vibrio parahaemolyticus.
There is currently no biodetector available today to rapidly detect these fast growing Vibrio bacteria in farms and hatcheries. MBI researchers have collaborated with leading microbiologists and aquaculture researchers to develop these EMS detection assays as well as assays for other aquaculture pathogens. These assays have been validated at the point-of-need by reputed aquaculture hatcheries and farming groups and are currently being sold and used worldwide by leading aquaculture companies from India, Thailand and USA.
In addition to detecting specific pathogens affecting aquaculture species, microbial management strategies may be employed by the hatchery owners with the help of Menon assays and systems. These strategies minimize the risk of EMS/AHPND and other disease outbreaks by continuous monitoring of the various microbial populations. On the other hand, by maintaining a larger population of slow-growing, safe bacteria in the pond, it is believed that EMS/AHPND and other disease outbreaks can be prevented. Thus, continuous monitoring of aquaculture hatcheries and ponds using MBI’s rapid, low-cost assays to detect and quantify microbial organisms is the strategy adopted by Menon customers for microbial management.
The recent article entitled, “Pathogen detection system at point‐of‐need for aquaculture applications” is available online for readers. The web link for the article is given below:
“This technology has a wide range of applications in aquaculture, food and water safety, animal healthcare, clinical point-of-care and bio-surveillance by rapidly detecting bacteria, viruses, fungi and parasites while delivering unmatched sensitivity, lowest-cost, fastest detection of nucleic acids compared to most of the nucleic acid methods available today” stated Dr. Suresh Menon, Ph.D., President of Menon Biosensors, Inc. Continued Dr. Menon. “We intend to expand marketing and sales of M2 technology for aquaculture worldwide in the coming months.”
About Menon Biosensors’ Platform Technology
M2 technology was developed initially to establish rapid countermeasures against bioterrorism. Menon’s technology provides superior results that enable officials to make intelligent, quick decisions following detection and exposure to lethal bacterial agents such as Anthrax (Bacillus anthracis) and Plague (Yersinia pestis). Testing of Menon’s biosensor technology to detect against bioterrorist attack became public information in a press release by the Department of Homeland Security in August 2012.
Menon Biosensors’ M2 technology has been validated through multiple studies with the U.S. government’s Biodefense Programs. In these studies, conducted with more than 3,000 samples over a six-year period, the technology demonstrated greater than 99 percent accuracy in the presence of interferants and near neighbors of the pathogens to be detected.
About Menon Biosensors, Inc.
Menon Biosensors is a molecular biochemistry company that provides DNA analysis for the diagnosis of biological pathogens. Menon Biosensors’ microfluidics and M2 NMR platform technology (classified by the U.S. Government until 2012) provides superior sensitivity and specificity and minimizes sample preparation, providing best in class sample-to-answer pathogen detection. The technology has been validated by respected third parties in more than 3,000 samples over six years.
858-675-9990 Ext 113